Dear Colleagues,
It is our pleasure to invite you to participate in The 3rd Immuno-Oncology World Congress (Immuno-Oncology2022) which will take place 2-3 November 2022 in Copenhagen, Denmark.
Immuno-Oncology2022 will focus on the latest developments and findings in immuno-oncology therapy as well as targeted therapy. The Congress will examine treatments available on the market as well as treatments still in the development stage. The Congress will welcome Oncologists, Dermatologists, Immunologists, Surgical Oncologists, clinical scientists, industry leaders and other experts.
![]() |
![]() |
Prof. Jacob Schachter
|
Prof. Dr. Dirk Schadendorf
|
Congress Agenda

Sheba Medical Center, Israel

Copenhagen University Hospital, Denmark


University Hospital Herlev & University of Copenhagen, Denmark

Sheba Medical Center, Israel

Tel Aviv University, Israel

Sheba Medical Center, Israel

University Hospital Essen, Germany

University Hospital Essen, Germany
Prof. Viktor Grünwald
Treatment of metastatic renal cell carcinoma (mRCC) has steadily evolved during the past decade. Today, 14 agents have received an EU-label for treatment of mRCC and are used in different lines of therapy. In 2019, ipilimumab + nivolumab (IO-IO) and axitinib + avelumab or pembrolizumab (TKI-IO) were approved for first line treatment and opened a new chapter in treatment perspectives in mRCC. Today’s first line treatment in mRCC offers a landscape with different outcome measures to achieve. While both strategies improved OS in patients, such benefit comes in different flavors. TKI-IO had profound impact on efficacy parameters, but complete response (CR) rates remain modest as of today. Furthermore, TKI-IO treatment comes at the expense of chronic TKI-toxicity, which impacts HR-QoL in patients. On the contrary, IO-IO had only modest impact on response rate, but achieved the highest CR rates reported so far. While IO-IO treatment is associated with its own AE spectrum, it achieves better HR-QoL compared to TKI treatment alone. Furthermore, the pivotal study has the longest follow-up and mirrors results seen in malignant melanoma, indicating a plateau. While the treatment landscape became more divers, early and late benefits can be identified with different treatment strategies, which are integral to our clinical decision making process. So, what is it going to be – CR or tumor control?

Sheba Medical Center, Israel

Papa Giovanni XXIII Hospital in Bergamo, Italy

Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI-AVL), Netherlands

LMU University Hospital Munich, Germany

European Institute of Oncology (IEO), Italy
Breast cancer is a heterogeneous disease, including a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, can cure most of patients, but, particularly in some subgroups like the triple negative or metastatic ones, effectiveness is not enough to impact on survival and more efforts are needed to develop alternative options.
Immunotherapy, as a novel strategy addressing the immune system, has demonstrated a strong potential in treating those highly mutated and immunogenic cancers.
Although breast cancer has long been considered a problematic target for immunotherapy, as it is immunologically “cold,” numerous recent preclinical and clinical reports now recommend that immunotherapy alone or in combination with chemotherapy, can be used to treat specific subsets of breast cancer patients.
Various strategies include not only immune-checkpoint inhibition with antiPD1s/PDL1s, but also vaccination and adoptive T-cell therapy (CAR-T).
Pembrolizumab, an anti-PD-1 human mAb, was tested in advanced triple negative patients. Expression of PD1 was detected in 60% of patients and efficacy in 27 cases: the overall response was 18.5%, with 1 complete remission reached. Atezolizumab, a human anti-PDL1, was tested with paclitaxel in 32 patients showing anti-tumor efficacy in 70% of TNBC patients. Avelumab, has been evaluated in a phase 2 clinical trial showing responses in 40 out of 168 patients (23.8%).
Several vaccine approaches, comprising of monovalent, polyvalent, and cellular vaccines, have been assessed, but results are not satisfactory due to the difficulties in identifying a set of tumor associated antigens able to personalize the treatment.
Adoptive T-cell transfer therapy is still on the run, mainly targeting HER2 positive tumors and new approaches using CAR-T seem effective and safe, meriting further development in clinical trials.

University Hospital Cologne, Germany

IRCCS San Matteo Pavia Foundation, Italy

Sheba Medical Center, Israel

Sheba Medical Center, Israel

EXPLORE COPENHAGEN

Contact Us
We look forward to hearing from you.